KDM4C and prostate carcinoma: Regarding the specificity and potency of the in vivo antitumor activity, SD70, a derivative of 8-hydroxyquinoline, specifically inhibits KDM4C (IC50 = 30 μM) and reduces the tumor size in a mouse xenograft model of prostate cancer [92].